76.50MMarket Cap-1.16P/E (TTM)
1.1136High0.9606Low339.73KVolume1.0600Open1.0900Pre Close342.64KTurnover0.87%Turnover RatioLossP/E (Static)75.00MShares2.750052wk High0.91P/B39.73MFloat Cap0.890052wk Low--Dividend TTM38.95MShs Float10.8700Historical High--Div YieldTTM14.04%Amplitude0.4700Historical Low1.0080Avg Price1Lot Size
Context Therapeutics Stock Forum
📊⚡️📊
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
BioAtla and Context Therapeutics have entered into an exclusive worldwide license agreement for the development and commercialization of BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody. Key points include:
1. Context obtains exclusive rights to BA3362
2. BioAtla to receive $15.0 million in upfront and ...
No comment yet